The free word cloud image of brain conditions for today’s offering header is courtesy of Google Images.
Health Friday is a series devoted to information about Big Pharma, vaccines, general health, and associated topics. There are Important Notifications from our host, Wolf Moon; the Rules of our late, good Wheatie; and, certain caveats from Yours Truly, of which readers should be aware. They are linked here. Note: AI-generated items in today’s offering will be cited as such. If readers wish to post AI-generated items in today’s discussion thread, they must cite their source. Thank you.
This mini series is dedicated to the memory of Yours Truly’s late brother, Samuel R. Lewis (24 November 1948 – 29 October 2024.) May he rest in eternal Peace. Love you, Sam. Miss you.
>>>>>>>>>>>>>>>>>>>>
Part One of this mini series is here: https://www.theqtree.com/2026/10/30/health-friday-10-30-2026-open-thread-the-covid-19-bioweapon-vaccines-and-dementia-part-one/; Part Two is here: https://www.theqtree.com/2026/11/06/health-friday-11-6-2026-open-thread-the-covid-19-bioweapon-vaccines-and-dementia-part-two/.
>>>>>>>>>>>>>>>>>>>>
The COVID-19 Bioweapon “Vaccines” and Dementia: Part Three, Section A
This section will discuss several Patents related to the Weissman-Kariko Patent for N1-methylpseudouridine granted on 13 July 2021 (the N1-methylpseudouridine formulation that is used in the Pfizer-BioNTech modRNA COVID-19 bioweapon “vaccines”; this Patent was applied for on 31 July 2017.) In no way is today’s offering to be construed as a “hit piece” on either Dr. Kariko or Dr. Sahin.
The Patents discussed in today’s offering are those held by Dr. Katalin Kariko, PhD, and/or by Dr. Ugur Sahin, MD. Dr. Kariko is on the faculty of the University of Pennsylvania, and is also a Senior Vice President of BioNTech. Dr. Sahin is CEO of BioNTech (also known as BioNTechSE), the German co-partner of PfizerUSA (Dr. Albert Bourla, DVM, is CEO of said co-partner.) Dr. Kariko’s biography, per the University of Pennsylvania’s Perelman School of Medicine, is here: https://www.pennmedicine.org/providers/katalin-kariko. Other websites that detail Dr. Kariko’s biography include https://www.nobelprize.org/. Biographies about Dr. Sahin include https://www.biontech.com/us/en/home/about/board-members.html, “Ugur Sahin.”
Dr. Ugur Sahin holds multiple US Patents related to the development of “cancer vaccines” for humans, all of which Patents involve the manipulation of RNA, and/or of immune system cells (CD4 – CD8), and/or the use of E. coli as a “culturing base” for a “cancer vaccine”, and so on. One example of Dr. Sahin’s Patents: https://patents.google.com/patent/WO2013143555A1/en, 26 March 2012, ceased 26 September 2014, “Rna formulation for immunotherapy”. This “cancer vaccine” invention utilizes several types of cationic lipid nanoparticles (DOPE; DOTMA; DOTAP; DOPC); the purpose of this “cancer vaccine” invention is, among other results, to vastly increase RNA expression in the lung, liver, and spleen; and, said “cancer vaccine” is to be used as a therapeutic treatment and/or as as prophylactic (Claim 1 through Claim 32.) Another example: https://patents.google.com/patent/WO2017059902A1/en, 13 April 2017, ceased 7 April 2018, another “cancer vaccine”; this is the E. coli “culturing base” Patent (Claim 14.) Yours Truly regards these Patents as “steps along the path” toward the Patent that is discussed below.
Dr. Katalin Kariko had been turned down for various research grants in the United States after previously working with Dr. Drew Weissman (also of the University of Pennsylvania.) She then went to Germany in 2013 to work with Dr. Sahin at BioNTech, while keeping her position at UPenn.
The Ugur – Kariko collaboration produced this Patent: https://patents.google.com/patent/EP3341026B1/en, “Method for reducing immunogenicity of adenosine rna”, 24 August 2016; Ugur Sahin and Katalin Kariko, inventors. This Patent is crucial in understanding the evolution of using N1-methylpseudouridine to eliminate the RNA of Uridine — which compound and mechanism is included in the Pfizer-BioNTech modRNA COVID-19 bioweapon “vaccine” formulas from the original BNT162b2 onward (which bioweapon “vaccine” was then approved by the FDA under the brand name COMIRNATY.) Exhibits from Patent EP3341026B1 are below, followed by Yours Truly’s comments. First, the Title and Date summary:

Claim 1 and Claim 2:


From the Summary:

From Brief Description of the Drawings, and the Figure 2:


From the Detailed Description:



Note following in the above, among other items: the entirety of Claim 1 and of Claim 2 (the elimination of Uridine and its replacement with a lab-created fake compound that has the same sequence configuration as that of the eliminated Uridine); section 0008, the substitution of / elimination of, Uridine; section 0053, the deliberate increase of adenosine (more on adenosine, below); section 0069, the listing of N1-methylpseudouridine; and, section 0102, the engineered-in potential for the cell’s genome to be altered by the transfected RNA.
>>>>>>>>>>>>>>>>>>>>
Adenosine
Adenosine is one of the “building blocks” of RNA: https://www.genscript.com/biology-glossary/12348/adenosine-monophosphate. Adenosine is important to the regulation and proper functioning of multiple areas and mechanisms of the body: https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/adenosine, “Adenosine Receptors in Neurology and Psychiatry”, Jiang-Fan Chen, et al.; 2014. Pullquote from this citation: “…adenosine contributes critically to homeostasis and neuromodulatory control of a variety of normal and abnormal brain functions…” — among them: sleep; cognition; and, neuroinflammation. Please see the screenshot, below, of a portion of this article: https://www.news-medical.net/health/What-is-Adenosine.aspx, Ananya Mandal, MD; Last Update 11 November 2026:

Refer back to Claim 1 of the Patent EP3341026B1, cited above with exhibits — in which adenosine in the “invention” is increased by at least 20%. A Yandex search of “what happens when adenosine is increased by 20%” yielded multiple results, a short Summary of which is imaged below:

Some of the above-listed references: One: increased inflammation: https://pmc.ncbi.nlm.nih.gov/articles/PMC2568887/, “Adenosine receptors: therapeutic aspects for inflammatory and immune diseases”, Gyorgy Hasko, et al.; 16 October 2008;
Two: increased cancer potential: https://encyclopedia.pub/entry/1401, which led to this paper: https://www.mdpi.com/1422-0067/21/14/5089, “The Adenosine System at the Crossroads of Intestinal Inflammation and Neoplasia”, Vanessa D’Antongiovanni, et al.; 18 July 2020; and,
Three: increased potential for neurological disorders: https://selfhacked.com/blog/adenosine-health-effects/, “Adenosine: Sleep, Receptors, Effects + 3 Ways to Increase”, Joe Cohen, B.S; 15 December 2020. A screenshot from the Cohen article is below:

**** What we have here is a Patent, EP3341026B1, invented by Katalin Kariko, PhD, and Ugur Sahin, MD, which Patent belongs to BioNTech SE (and is in force until August 2036): that is, in Yours Truly’s opinion, the template for the Weissman-Kariko Patent for N1-methylpseudouridine (which Patent application was made in 2017, granted in 2021, AND which Patent is the basis for the N1-methylpseudouridine in the Pfizer-BioNTech modRNA COVID-19 bioweapon “vaccine” BNT162b2) — but also, Yours Truly believes, is part of the template for BNT162b2 itself. This is the same BNT162b2 that was then approved by the FDA under the brand name COMIRNATY. The same COMIRNATY that is the “2026-2027 latest variant booster COVID-19 vaccine” which was approved by the FDA on 27 August 2026 — an FDA approval that was granted with no human trials having been performed: the only “studies” that were conducted by Pfizer-BioNTech were performed on a few lab mice. Confirmation regarding this last: https://www.thefocalpoints.com/p/breaking-fda-approves-new-pfizer, “BREAKING: FDA Approves New Pfizer and Moderna XFG mRNA COVID Shots Based on Data From Just 8 – 10 Mice”, Nicolas Hulscher, MPH, 27 August 2026.
To be continued in Part Three, Section B.
Peace, Good Energy, Respect: PAVACA1
(Intellectual Property Disclaimer and Notice: Except for linked URLs and other items in today’s offering that are available on the Internet, the ideas and/or opinions above are by PAVACA1. Credit must be given to PAVACA1 if ideas and/or opinions in today’s offering are used by other blog writers; by podcasters; or in print or social media.)


















































































